- Statement of Changes in Beneficial Ownership (4)
21 April 2012 - 6:33AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden
hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
HRUSOVSKY E KEVIN
|
2. Issuer Name
and
Ticker or Trading Symbol
SERACARE LIFE SCIENCES INC
[
SRLS
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__
X
__ Director
_____ 10% Owner
_____ Officer (give title below)
_____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O SERACARE LIFE SCIENCES, INC., 37 BIRCH STREET
|
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/20/2012
|
(Street)
MILFORD, MA 01757
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security
(Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code
(Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock
|
4/20/2012
|
|
D
|
|
2739
|
D
|
(1)
|
0
|
D
|
|
Table II - Derivative Securities Beneficially Owned (
e.g.
, puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security
(Instr. 3)
|
2. Conversion or Exercise Price of Derivative Security
|
3. Trans. Date
|
3A. Deemed Execution Date, if any
|
4. Trans. Code
(Instr. 8)
|
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
|
6. Date Exercisable and Expiration Date
|
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
|
8. Price of Derivative Security
(Instr. 5)
|
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)
|
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)
|
11. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
(A)
|
(D)
|
Date Exercisable
|
Expiration Date
|
Title
|
Amount or Number of Shares
|
Stock Option (Right to Buy)
|
$2.73
|
4/20/2012
|
|
D
|
|
|
3750
|
(3)
|
11/16/2016
|
Common Stock
|
3750
|
(4)
|
0
|
D
|
|
Stock Option (Right to Buy)
|
$2.73
|
4/20/2012
|
|
D
|
|
|
11250
|
(2)
|
11/16/2016
|
Common Stock
|
11250
|
(4)
|
0
|
D
|
|
Stock Option (Right to Buy)
|
$3.86
|
4/20/2012
|
|
D
|
|
|
7890
|
(3)
|
11/17/2015
|
Common Stock
|
7890
|
(4)
|
0
|
D
|
|
Explanation of Responses:
|
(
1)
|
Pursuant to the Agreement and Plan of Merger dated as of February 12, 2012, as amended by Amendment No. 1 to Agreement and Plan of Merger dated as of February 27, 2012, among SeraCare Life Sciences, Inc., Project Plasma Holdings Corporation and Project Plasma Merger Corp. (the "Merger Agreement"), each share of SeraCare Life Sciences, Inc.'s common stock was exchanged for $4.00 in cash, without interest and less any applicable withholding taxes.
|
(
2)
|
Pursuant to its terms, the stock option accelerated and became fully vested as of the closing of the merger.
|
(
3)
|
This stock option is fully vested.
|
(
4)
|
Pursuant to the Merger Agreement, each stock option was cancelled in the merger in exchange for the right to receive an amount in cash, without interest, equal to the product of the number of shares issuable upon the exercise of such stock option and $4.00 minus the exercise price of such stock option, less any applicable withholding taxes.
|
Reporting Owners
|
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
HRUSOVSKY E KEVIN
C/O SERACARE LIFE SCIENCES, INC.
37 BIRCH STREET
MILFORD, MA 01757
|
X
|
|
|
|
Signatures
|
/s/ Gregory A. Gould, Attorney-in-fact
|
|
4/20/2012
|
**
Signature of Reporting Person
|
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
|
*
|
If the form is filed by more than one reporting person,
see
Instruction 4(b)(v).
|
**
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations.
See
18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
Note:
|
File three copies of this Form, one of which must be manually signed. If space is insufficient,
see
Instruction 6 for procedure.
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
|
Seracare Life Sciences (NASDAQ:SRLS)
Historical Stock Chart
From May 2024 to Jun 2024
Seracare Life Sciences (NASDAQ:SRLS)
Historical Stock Chart
From Jun 2023 to Jun 2024
Real-Time news about Seracare Life Sciences (MM) (NASDAQ): 0 recent articles
More News Articles